CA Patent

CA2144669A1 — Biphenyl derivatives

Assigned to Eisai Co Ltd · Expires 1995-09-30 · 31y expired

What this patent protects

A biphenyl derivative represented by the following formula (I) or a pharmacologically acceptable salt thereof: (I) wherein R1 represents a hydrogen atom, a halogen atom, a hydroxyl group, an amino group, a lower alkyl group, a halogenated lower alkyl group, a lower alkoxy g…

USPTO Abstract

A biphenyl derivative represented by the following formula (I) or a pharmacologically acceptable salt thereof: (I) wherein R1 represents a hydrogen atom, a halogen atom, a hydroxyl group, an amino group, a lower alkyl group, a halogenated lower alkyl group, a lower alkoxy group, a halogenated lower alkoxy group, a lower alkoxyalkyl. group, a lower alkoxyalkoxy group, an aryl group, an aralkyl group, a heteroaryl group, a heteroarylalkyl group, a halogenated heteroarylalkyl group, a cyano lower alkyl group, a hydroxy lower alkyl group, an amino lower alkyl group, a lower alkoxycarbonyl group, an aryloxycarbonyl group, a cyano group, a formyl group, a lower acyl group, an aralkylcarbonyl group, cycloether group, an alkenyl group, an alkynyl group. a lower alkylsulfinyl group, a lower alkylsulfonyl group, a lower alkylaminosulfonyl group, an arylarnino-sulfonyl group, a lower alkylsulfonylamino group, a halogenated lower alkylsulfonylamino group or an arylsulfonylamino group; R2 and R3 may be the same or different from each other and each represents a hydrogen atom, a halogen atom, a lower alkyl group, a halogenated lower alkyl group, a lower alkoxy group, a halogenated lower alkoxy group or a cyano group; R4 represents a hydrogen atom or a halogen atom; R5 represents a hydrogen atom, a lower alkyl group, a halogenated lower alkyl group, a hydroxy lower alkyl group, a lower alkoxycarbonyl group or an aryloxy-carbonyl group; and n is 0 or an integer of 1 to 3, which exhibits dopamine 2 receptor antagonism and/or serotonin 2 receptor antagonism, is clinically useful for treating and ameliorating mental disorders such as cerebrovascular disorder, aggressive behavior due to senile dementia, mental excitation, poriomania, delirium, hallucination, hyperkinesia, schizophrenia, emotional disturbance, depression, neurosis, psycho-physiologic disorder and anxiety neurosis.

Drugs covered by this patent

Patent Metadata

Patent number
CA2144669A1
Jurisdiction
CA
Classification
Expires
1995-09-30
Drug substance claim
No
Drug product claim
No
Assignee
Eisai Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.